206 related articles for article (PubMed ID: 32348888)
1. Cerebellar Pleomorphic Xanthoastrocytoma with BRAF V600E Mutation.
Kim SH; Hwang K; Lee KS; Choe G; Kim CY
World Neurosurg; 2020 Jul; 139():577-581. PubMed ID: 32348888
[TBL] [Abstract][Full Text] [Related]
2. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
[TBL] [Abstract][Full Text] [Related]
3. Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation: case report.
Cicuendez M; Martinez-Saez E; Martinez-Ricarte F; Asanza EC; Sahuquillo J
J Neurosurg Pediatr; 2016 Jul; 18(1):53-7. PubMed ID: 27015517
[TBL] [Abstract][Full Text] [Related]
4. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
[TBL] [Abstract][Full Text] [Related]
5. BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study.
Ma C; Feng R; Chen H; Hameed NUF; Aibaidula A; Song Y; Wu J
World Neurosurg; 2018 Dec; 120():e1225-e1233. PubMed ID: 30240866
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E mutation: A treatable driver mutation in pleomorphic xanthoastrocytoma (PXA).
Hofer S; Berthod G; Riklin C; Rushing E; Feilchenfeldt J
Acta Oncol; 2016; 55(1):122-3. PubMed ID: 25811650
[No Abstract] [Full Text] [Related]
7. Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
Yamada S; Kipp BR; Voss JS; Giannini C; Raghunathan A
Am J Surg Pathol; 2016 Feb; 40(2):279-84. PubMed ID: 26414224
[TBL] [Abstract][Full Text] [Related]
8. Cerebellar pleomorphic xanthoastrocytoma in the setting of neurofibromatosis type-I: Does it portend a different prognosis? A case report and systematic review.
Mathkour M; Banerjee S; Werner C; Hanna J; Abou-Al-Shaar H; Dindial R; Scullen T; Boehm L; Tubbs RS; Ware ML
Clin Neurol Neurosurg; 2021 Jan; 200():106346. PubMed ID: 33160715
[TBL] [Abstract][Full Text] [Related]
9. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.
Dias-Santagata D; Lam Q; Vernovsky K; Vena N; Lennerz JK; Borger DR; Batchelor TT; Ligon KL; Iafrate AJ; Ligon AH; Louis DN; Santagata S
PLoS One; 2011 Mar; 6(3):e17948. PubMed ID: 21479234
[TBL] [Abstract][Full Text] [Related]
10. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.
Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D
Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma.
Furuta T; Miyoshi H; Komaki S; Arakawa F; Morioka M; Ohshima K; Nakada M; Sugita Y
Neuropathology; 2018 Jun; 38(3):218-227. PubMed ID: 29532523
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
[TBL] [Abstract][Full Text] [Related]
13. Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.
Brown NF; Carter T; Mulholland P
CNS Oncol; 2017 Jan; 6(1):5-9. PubMed ID: 27781490
[TBL] [Abstract][Full Text] [Related]
14. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation.
Tanaka S; Nakada M; Nobusawa S; Suzuki SO; Sabit H; Miyashita K; Hayashi Y
Brain Tumor Pathol; 2014 Jul; 31(3):172-6. PubMed ID: 24894018
[TBL] [Abstract][Full Text] [Related]
15. Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.
Ida CM; Rodriguez FJ; Burger PC; Caron AA; Jenkins SM; Spears GM; Aranguren DL; Lachance DH; Giannini C
Brain Pathol; 2015 Sep; 25(5):575-86. PubMed ID: 25318587
[TBL] [Abstract][Full Text] [Related]
16. MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.
Lohkamp LN; Schinz M; Gehlhaar C; Guse K; Thomale UW; Vajkoczy P; Heppner FL; Koch A
PLoS One; 2016; 11(6):e0156422. PubMed ID: 27253461
[TBL] [Abstract][Full Text] [Related]
17. Cerebellar pleomorphic xanthoastrocytoma in a patient with neurofibromatosis type 1: a case report and literature review.
Takei H; Rouah E; Bhattacharjee MB
Int J Clin Exp Pathol; 2015; 8(6):7570-4. PubMed ID: 26261671
[TBL] [Abstract][Full Text] [Related]
18. Composite pleomorphic xanthoastrocytoma-epithelioid glioneuronal tumor with BRAF V600E mutation - report of three cases.
Aisner DL; Newell KL; Pollack AG; Kleinschmidt-Demasters BK; Steinberg GK; Smyth LT; Vogel H
Clin Neuropathol; 2014; 33(2):112-21. PubMed ID: 24321241
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas.
Lee D; Cho YH; Kang SY; Yoon N; Sung CO; Suh YL
J Surg Oncol; 2015 Mar; 111(3):359-64. PubMed ID: 25346165
[TBL] [Abstract][Full Text] [Related]
20. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression.
Chappé C; Padovani L; Scavarda D; Forest F; Nanni-Metellus I; Loundou A; Mercurio S; Fina F; Lena G; Colin C; Figarella-Branger D
Brain Pathol; 2013 Sep; 23(5):574-83. PubMed ID: 23442159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]